Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Inside The FDA: Spectrum Pharmaceuticals, Inc. (SPPI) and its Bladder Cancer Treatment, Apaziquone

Page 1 of 3

On September 14, 2016, the FDA’s Oncologic Drugs Advisory Committee met to evaluate and discuss a drug called apaziquone. Apaziquone is a development stage bladder cancer treatment, which small cap biotech Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is investigating as a therapy designed to reduce the risk of recurrence of bladder cancer in patients that have juts undergone surgery to remove small, low grade, bladder cancer tumors. The advisory panel voted against approval, and the FDA will report its final ruling by way of a December 11, 2016 PDUFA.

Ahead of the PDUFA, here’s our take on apaziquone, and an unwinding of the briefing document put together by the agency.

First up, let’s take a look at the indication – bladder cancer.


The drug is targeting hat’s called non-muscle invasive bladder cancer (NMIBC), which as its name suggests, is a type of bladder cancer that is limited to, and bound by, bladder tissue, and which has not spread to surrounding muscle tissue. Specifically, in this instance, apaziquone is designed to treat a low grade of the disease, as defined by the International Society of Urological Pathology 2004 WHO grading system:


I the US, an estimated 76,960 adults (58,950 men and 18,010 women) will be diagnosed with bladder cancer each year, and 6,390 deaths (11,820 men and 4,570 women) from the disease occur every year. It is the fourth most common cancer among men, and for reasons as yet undetermined (at least, that is, with any degree of certainty) it’s far more prevalent among men than women.

The current standard of care therapy for this degree of bladder cancer is resection – a surgeon goes in and cuts out as much of the cancerous matter as possible, with the goal obviously being to remove all the tumor cells. There’s a real issue with recurrence, however, and it primarily revolves around the cells that come loose while the physician is cutting away the primary tumor or tumors. These cells lodge back in to the bladder tissue, and form fresh tumors.

In an effort to avoid this recurrence, some physician will use off label chemotherapy drugs as a sort of post-surgery wash out, flushing the bladder with the drugs in question in an attempt to kill any erroneous cancer cells. We’re going to discuss this in a little more detail shortly, but for reference, the drugs most used are epirubicin and mitomycin – to well established and widely used chemo agents. It’s important to note here that the use of these two drugs in this instance, what’s called intravesical chemotherapy, is not approved by the FDA. Physicians administer the intravesical chemotherapy to minimize the chances of recurrence, but there have been no trials (to date) that prove the method is safe and effective. It’s assumed safe, based on the established nature of the drugs in question, and the efficacy assumption is based on meta analysis.

So with that out of the way, let’s move on to apaziquone.

Page 1 of 3

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!